Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
Antibe Therapeutics Inc. (OTCQX: ATBPF) announced its participation in the Canaccord Genuity 41st Annual Growth Conference, taking place virtually from August 10-12, 2021. CEO Dan Legault and CMO Dr. Joseph Stauffer will present on August 12 at 9:00 am Eastern Time. A webcast link will be available on the company's website, with a replay accessible for 90 days after the event. Antibe is focused on developing safer therapies for inflammatory conditions using its hydrogen sulfide platform, with a pipeline that includes treatments for osteoarthritis pain and alternatives to NSAIDs.
- None.
- None.
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10 - 12. Dan Legault, Antibe’s CEO, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company’s presentation:
Date: Thursday, August 12, 2021
Time: 9:00 am (Eastern Time)
A link to the webcast of the presentation will be available on the News and Events section of the Company’s website at antibethera.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.
About Antibe Therapeutics Inc.
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development for the treatment of osteoarthritis pain. Additional assets include a safer alternative to opioids for peri-operative pain, and a GI-sparing alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005190/en/
FAQ
When is Antibe Therapeutics participating in the Canaccord Genuity conference?
What time is Antibe Therapeutics' presentation at the Canaccord Genuity conference?
Where can I find the webcast for Antibe Therapeutics' conference presentation?
What is Antibe Therapeutics known for?
What are the key products in Antibe Therapeutics' pipeline?
